Yanbin Zhu

Yanbin Zhu


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in International Journal of Biological Sciences
Verified
Journal Article
Open access
PDF file
JCJianpeng Chen
Jianpeng Chen
DWDengying Wu
Dengying Wu
CHChengbin Huang
Chengbin Huang
ZYZijian Yan
Zijian Yan
JWJiahao Wang
Jiahao Wang
ZHZhiyong Hou
Zhiyong Hou
Disuse osteoporosis (DOP), a skeletal disorder triggered by insufficient mechanical loading, manifests as progressive bone mass deterioration and microarchitectural weakening. Piezo1, a key mechanosensitive ion channel expressed in bone cells, is implicated in maintaining skeletal homeostasis. Using a murine hindlimb unloading (HLU) model simulating microgravity-induced bone loss, we observed significant downregulation of Piezo1 expression in bone tissue and isolated bone marrow-derived mesenchymal stem cells (BMSCs). Systemic administration of the Piezo1 agonist Yoda1 attenuated HLU-induced osteopenia and improved bone formation capacity. Mechanistic studies in BMSCs demonstrated that Piezo1 activation promoted mitochondrial biogenesis. This effect required AMPK/SIRT1 signaling-dependent deacetylation of PGC-1α, leading to enhanced mitochondrial function, improved osteogenic differentiation, and reduced apoptosis. Critically, pharmacologic inhibition of SIRT1 abolished the osteoprotective effects of Yoda1 in vivo. These findings establish that mechanical unloading impairs Piezo1-mediated mechanotransduction in BMSCs, contributing to disrupted skeletal homeostasis, which can be mitigated by exogenous Piezo1 activation. Our results define a mechanism where Piezo1 integrates mechanical signals into the AMPK/SIRT1/PGC-1α signaling cascade to regulate mechanoadaptive bone formation, highlighting Piezo1 activation as a potential mechanism-based therapeutic strategy for disuse osteoporosis.

1 November 2024 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
QSQingcheng Song
Qingcheng Song
YZYiran Zhang
Yiran Zhang
HHHongzhi Hu
Hongzhi Hu
XYXuemei Yang
Xuemei Yang
XXXin Xing
Xin Xing
ZHZhiyong Hou
Zhiyong Hou
Introduction: Ferroptosis-driven tumor ablation strategies based on nanotechnology could be achieved by elevating intracellular iron levels or inhibiting glutathione peroxidase 4 (GPX4) activity. However, the intracellular antioxidative defense mechanisms endow tumor cells with ferroptosis resistance capacity. The purpose of this study was to develop a synergistic therapeutic platform to enhance the efficacy of ferroptosis-based tumor therapy. Methods: In this study, a multifunctional nano-catalytic therapeutic platform (mFeB@PDA-FA) based on chemodynamic therapy (CDT) and photothermal therapy (PTT) was developed to effectively trigger ferroptosis in tumor. In our work, iron-based mesoporous Fe3O4 nanoparticles (mFe3O4 NPs) were employed for the encapsulation of L-buthionine sulfoximine (BSO), followed by the modification of folic acid-functionalized polydopamine (PDA) coating on the periphery. Then, the antitumor effect of mFeB@PDA-FA NPs was evaluated using Human OS cells (MNNG/HOS) and a subcutaneous xenograft model of osteosarcoma. Results: mFe3O4 harboring multivalent elements (Fe2+/3+) could catalyze hydrogen peroxide (H2O2) into highly cytotoxic ˙OH, while the tumor microenvironment (TME)-responsive released BSO molecules inhibit the biosynthesis of GSH, thus achieving the deactivation of GPX4 and the enhancement of ferroptosis. Moreover, thanks to the remarkable photothermal conversion performance of mFe3O4 and PDA shell, PTT further synergistically enhanced the efficacy of CDT and facilitated ferroptosis. Both in vivo and in vitro experiments confirmed that this synergistic therapy could achieve excellent tumor inhibition effects. Conclusion: The nanotherapeutic platform mFeB@PDA-FA could effectively disrupted the redox homeostasis in tumor cells for boosting ferroptosis through the combination of CDT, PTT and GSH elimination, which provided a new perspective for the treatment of ferroptosis sensitive tumors.

24 June 2025 in ACS Applied Materials & Interfaces
Verified
Journal Article
Open access
QSQingcheng Song
Qingcheng Song
YZYiran Zhang
Yiran Zhang
HHHongzhi Hu
Hongzhi Hu
XXXin Xing
Xin Xing
JWJianhua Wu
Jianhua Wu
ZHZhiyong Hou
Zhiyong Hou
The regeneration of bone defects remains an enormous clinical challenge owing to locally abnormal reactive oxygen species (ROS) levels and the inability to timely regulate the osteoimmune microenvironment. Herein, polydopamine (PDA) modified black phosphorus nanosheets (BP) with small palladium nanoparticles (Pd NPs) immobilized in situ were prepared (BP@PDA-Pd) and incorporated into a gelatin methacryloyl/methacrylated poly-γ-glutamate hybrid hydrogel to fabricate a composite photocurable therapeutic platform (BPPP/GP) with excellent antioxidant and osteo-immunomodulatory activity for enhanced high-quality endogenous bone regeneration. The BPPP with optical absorbance in the near-infrared (NIR) region endows the composite hydrogel with excellent NIR-responsive characteristics, resulting in mild photothermal-enhanced antioxidant enzyme-like activity to scavenge ROS and the induction of endogenous cell recruitment. More importantly, the BPPP/GP photocurable hydrogel with mild photothermal stimulation could achieve spatiotemporal regulation of the osteoimmune microenvironment by inducing macrophage polarization toward the anti-inflammatory phenotype (M2), with the secretion of pro-osteogenic and pro-angiogenic growth factors. In vivo experiments confirmed that the NIR-stimulation based BPPP/GP system could effectively eliminate ROS, alleviate local inflammation, and regulate macrophage polarization to create a favorable osteoimmune microenvironment for osteogenic differentiation and revascularization. Together, the development of this multifunctional hydrogel with the capability to reshape the damaged microenvironment provides a promising strategy for accelerating bone regeneration.

24 September 2025 in Bone Research
Verified
Journal Article
Open access
PDF file
TZTao Zhang
Tao Zhang
HLHongzhi Lv
Hongzhi Lv
SJSiming Jia
Siming Jia
LWLijun Wang
Lijun Wang
WLWeijian Liu
Weijian Liu
YZYanbin Zhu
Yanbin Zhu
Piezo1, a key mechanosensor in bone homeostasis, plays a crucial role in fracture healing. However, the mechanisms through which Piezo1 regulates chondrocytes and affects endochondral ossification remain poorly understood. This study aimed to investigate the regulatory mechanisms of Piezo1 in chondrocytes during endochondral ossification. Using lineage tracing, we identified chondrocyte-to-osteoblast transdifferentiation during endochondral ossification, which was impaired by chondrocyte-specific Piezo1 knockout. Piezo1 deficiency disrupted mitochondrial bioenergetics, characterized by diminished membrane potential, reduced adenosine triphosphate (ATP) synthesis, suppressed oxygen consumption rates (basal and maximal respiration), and elevated mitochondrial superoxide generation, thereby impairing endochondral ossification during fracture healing. Single-cell RNA sequencing revealed upregulated Lars2 expression in hypertrophic chondrocytes following Piezo1 knockout. Inhibition of Lars2 in chondrocytes normalized mitochondrial dynamics-related markers (MFN1, MFN2, OPA1, DRP1) and restored mitochondrial functional homeostasis. This intervention concurrently reversed Piezo1 knockout-induced suppression of osteogenic markers (Col1, ALP, OCN, OPN, RUNX2), thereby enhancing fracture repair. Protein interaction analyses confirmed direct binding between β-catenin and Lars2. Mechanistically, Piezo1 governs Lars2 expression via β-catenin signaling. Our findings demonstrate that Piezo1 activation via Yoda1 enhances mitochondrial bioenergetics and accelerates fracture repair through the β-catenin/Lars2 axis, offering novel insights and therapeutic avenues for fracture treatment.

26 September 2025 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
CHChengbin Huang
Chengbin Huang
XCXuankuai Chen
Xuankuai Chen
DWDengying Wu
Dengying Wu
JCJianpeng Chen
Jianpeng Chen
JWJiahao Wang
Jiahao Wang
ZHZhiyong Hou
Zhiyong Hou

18 November 2025 in Materials Today Bio
Verified
Journal Article
Open access
QSQingcheng Song
Qingcheng Song
SZShuo Zhang
Shuo Zhang
JYJiahao Yu
Jiahao Yu
YZYiran Zhang
Yiran Zhang
CFChunxu Fu
Chunxu Fu
ZHZhiyong Hou
Zhiyong Hou
The treatment of osteoporotic bone defects represents a substantial clinical challenge in contemporary orthopedics due to the abnormal accumulation of reactive oxygen species (ROS) and elevated inflammatory levels. Despite advances in bone graft materials for enhancing bone regeneration, developing an ideal therapeutic strategy capable of orchestrating the multidimensional biological processes underlying bone healing, such as immunomodulation, angiogenesis, osteogenesis and innervation, remains a formidable challenge in orthopedic biomaterial design. In our study, a multifunctional composite hydrogel (Ce@Mo/GC) was developed through the incorporation of CeO2@Mo2Ti2C3 MXene (Ce@Mo) heterojunction structures into gelatin methacryloyl (GelMA)/carboxymethyl chitosan (CMCS) for optimizing the osteogenic microenvironment in osteoporotic bone defects. The Ce@Mo system integrates multiple enzyme-like activities with NIR-responsive photothermal effects, enabling effective ROS scavenging at defect sites through mild hyperthermia-enhanced Ce3+/Ce4+ valence transitions in CeO2, while promoting macrophage polarization to M2 phenotype to modulate immune responses. Additionally, localized administration of Ce@Mo/GC can promote bone healing by inducing neurogenesis in the defect site and triggering the spatiotemporal release of neuropeptides through mild photothermal stimulation. Both in vitro and in vivo experiments demonstrated that the Ce@Mo/GC hydrogel exhibits excellent biocompatibility while effectively modulating inflammatory responses, promoting osteogenic differentiation, angiogenesis and achieving nerve immune regulation to promote bone healing.